Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM

Oxford, UK- 24 April 2009 - PharmaVentures Ltd, announced today that it has been engaged by Merck & Co, Inc. to advise and assist in divesting its world class research centre, the IRBM, located near Rome, Italy. The engagement will utilise PharmaVentures' pharmaceutical transactions experience in the healthcare and investment business sectors. The IRBM is an integrated, state-of-the-art small molecule and biological discovery centre. IRBM has an outstanding record of drug discovery including Isentress(R), the first approved HIV integrase inhibitor and winner of the Prix Galien USA 2008 award for the best pharmaceutical agent. The centre has received significant investment since 2000 and is staffed with exceptional, experienced pharmaceutical scientists.

Good deal for Merck and Schering-Plough?

Merck & Co and Schering-Plough have announced that they are to merge in a deal worth US$41.1 B. It's a deal that has been long speculated because of their existing marketing relationships over Zetia® and Vytorin® and the opportunity of potential cost savings. The combined company will generate sales of US$47 B.

Pfizer - Wyeth: Good Deal or Bad Deal?

If Pfizer and Wyeth merge to create a $60 billion company, will it be a good deal or a bad deal? Fintan Walton, PhD, CEO of PharmaVentures, says, ‘This is potentially a bad deal for both companies.'

Determining Valuations in Challenging Times

In today's financial climate, the survival of smaller companies is often dependent on their ability to do deals successfully with larger pharmaceutical companies.

Major New Report Highlights Growing Importance of IP Strategies and Competition Law in the Pharmaceuticals Industry

PharmaVentures announced today the publication of the report ‘Competition Law and Intellectual Property Strategy in the Pharmaceuticals Sector’, written by Richard Eccles and Gerry Kamstra, partners in the leading international law firm, Bird & Bird

PharmaVentures acted as advisor for sale of PhotoBioChem, N.V. patent assets to SpectraCure, AB

PharmaVentures announced today that it had acted as an advisor and broker to PhotoBioChem, N.V. Holland for the sale of its patent assets to SpectraCure AB, Sweden.

PharmaVentures acted as advisor for sale of Dowpharma Small Molecules business to Dr Reddy’s Laboratories

PharmaVentures announced today that it acted as advisor to the Dow Chemical Company (NYSE:DOW) for the sale of Dowpharma Small Molecules business to Dr. Reddy’s Laboratories (NYSE:RDY).

Anne Vindenes Allen Joins PharmaVentures Ltd to Head Publishing Operations

PharmaVentures announced today the appointment of Anne Vindenes Allen MSc as Chief Operating Officer of PharmaDeals, the new publishing division of PharmaVentures Ltd. Fintan Walton, PhD, PharmaVentures’ Chief Executive Officer says, “We have a large and loyal following for the PharmaDeals database within the pharmaceutical and biotechnology business sector, and have plans to roll out some truly exciting developments in the coming months. We are delighted Anne will join us to steer these developments. Her experience of managing complex web technology implementations combined with her publishing expertise will be invaluable in helping us position our products to better serve our discerning customers.”

PharmaVentures Launches Bespoke Analysis Service

With over 24,000 deals and alliances completed in the Life Science industry over the past 10 years, current and readily available statistics and insight is an essential part of business development. PharmaVentures, a leading provider of specialist consultancy and intelligence services, has launched a bespoke on-demand, 48 hour turn-around analysis service, PharmaDeals® Research.

PharmaTelevision Celebrates its One Year Anniversary

The revolutionary global media channel for the pharmaceutical and biotech industry, PharmaTelevision, is celebrating its one year anniversary. Launched on May 18th 2006 and with viewing figures now averaging 8,000 per programme, the site is fast becoming one of the most popular channels for insight and intelligence across the industry.

Pages

 

_

PharmaVentures InSights